share_log

Morgan Stanley Initiates Coverage On Dyne Therapeutics With Overweight Rating, Announces Price Target of $40

Benzinga ·  Apr 30 05:17

Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announces Price Target of $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment